Natural Killer Cells in Viral Hepatitis

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 6, 2015, Pages 578-588

  Rehermann, Barbara ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

HBV; HCV; Infection; Interferon; T Cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BETA INTERFERON; DEATH RECEPTOR 5; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; STAT4 PROTEIN; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE HEPATITIS B; ACUTE HEPATITIS C; ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SPECIFICITY; CHRONIC HEPATITIS B; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HEALTH CARE QUALITY; HEPATITIS B VIRUS; HEPATITIS C; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LONG TERM EXPOSURE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH2 CELL; VIRAL CLEARANCE; VIRUS GENE; VIRUS HEPATITIS;

EID: 84944449107     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.09.004     Document Type: Review

References (114)

1. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-117.
2. Kiessling R., Klein E., Pross H., et al. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
3. Eberl G., Colonna M., Di Santo J.P., et al. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 2015, 348:aaa6566.
4. Artis D., Spits H. The biology of innate lymphoid cells. Nature 2015, 517:293-301.
5. Diefenbach A. Profiling the diversity of innate lymphoid cells. Nat Immunol 2015, 16:222-224.
6. Gordon S.M., Chaix J., Rupp L.J., et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012, 36:55-67.
7. Klose C.S., Flach M., Mohle L., et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014, 157:340-356.
8. Marquardt N., Beziat V., Nystrom S., et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 2015, 194:2467-2471.
9. Vivier E., Raulet D.H., Moretta A., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
10. Paust S., Gill H.S., Wang B.Z., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010, 11:1127-1135.
11. Peng H., Jiang X., Chen Y., et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013, 123:1444-1456.
12. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
13. Lee J., Zhang T., Hwang I., et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015, 42:431-442.
14. Luetke-Eversloh M., Hammer Q., Durek P., et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 2014, 10:e1004441.
15. Schlums H., Cichocki F., Tesi B., et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015, 42:443-456.
16. Beaulieu A.M., Madera S., Sun J.C. Molecular programming of immunological memory in natural killer cells. Adv Exp Med Biol 2015, 850:81-91.
17. Bryceson Y.T., March M.E., Ljunggren H.G., et al. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73-91.
18. Horowitz A., Strauss-Albee D.M., Leipold M., et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 2013, 5:208ra145.
19. Biron C.A., Nguyen K.B., Pien G.C., et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17:189-220.
20. Khakoo S.I., Thio C.L., Martin M.P., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
21. Knapp S., Warshow U., Ho K.M., et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011, 141:320-325.
22. Ahlenstiel G., Titerence R.H., Koh C., et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010, 138:325-335.
23. - natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. J Hepatol 2014, 61:475-481.
24. Sugden P.B., Cameron B., Mina M., et al. Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users. J Hepatol 2014, 61:738-745.
25. Golden-Mason L., Cox A.L., Randall J.A., et al. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010, 52:1581-1589.
26. Werner J.M., Heller T., Gordon A.M., et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology 2013, 58:1621-1631.
27. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001, 75:7059-7066.
28. Su A.I., Pezacki J.P., Wodicka L., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002, 99:15669-15674.
29. Horner S.M., Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013, 19:879-888.
30. Schoggins J.W., MacDuff D.A., Imanaka N., et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014, 505:691-695.
31. Park S.H., Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014, 40:13-24.
32. Thimme R., Bukh J., Spangenberg H.C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002, 99:15661-15668.
33. Diepolder H.M., Zachoval R., Hoffmann R.M., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346:1006-1007.
34. Missale G., Bertoni R., Lamonaca V., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996, 98:706-714.
35. Urbani S., Amadei B., Fisicaro P., et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006, 44:126-139.
36. Kaplan D.E., Sugimoto K., Newton K., et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 2007, 132:654-666.
37. Thimme R., Oldach D., Chang K.M., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
38. Amadei B., Urbani S., Cazaly A., et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010, 138:1536-1545.
39. Pelletier S., Drouin C., Bedard N., et al. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol 2010, 53:805-816.
40. Kokordelis P., Kramer B., Korner C., et al. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology 2014, 59:814-827.
41. Varchetta S., Mele D., Mantovani S., et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012, 56:841-849.
42. De Maria A., Fogli M., Mazza S., et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007, 37:445-455.
43. Nattermann J., Feldmann G., Ahlenstiel G., et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006, 55:869-877.
44. Oliviero B., Varchetta S., Paudice E., et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151-1156.
45. Beziat V., Dalgard O., Asselah T., et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2012, 42:447-457.
46. Golden-Mason L., Stone A.E., Bambha K.M., et al. Race- and gender-related variation in NKp46 expression associated with differential anti-HCV immunity. Hepatology 2012, 56:1214-1222.
47. Hudspeth K., Donadon M., Cimino M., et al. Human liver-resident CD56/CD16 NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2015, Published online. http://dx.doi.org/10.1016/j.jaut.2015.08.011.
48. Morishima C., Paschal D.M., Wang C.C., et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006, 43:573-580.
49. Serti E., Chepa-Lotrea X., Kim Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015, 149:190-200.
50. Fauriat C., Long E.O., Ljunggren H.G., et al. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
51. + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
52. Bonorino P., Ramzan M., Camous X., et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009, 51:458-467.
53. Dessouki O., Kamiya Y., Nagahama H., et al. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem Biophys Res Comm 2010, 393:331-337.
54. Sene D., Levasseur F., Abel M., et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog 2010, 6:e1001184.
55. Edlich B., Ahlenstiel G., Azpiroz A.Z., et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012, 55:39-48.
56. Miyagi T., Takehara T., Nishio K., et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010, 53:424-430.
57. Miyagi T., Gil M.P., Wang X., et al. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med 2007, 204:2383-2396.
58. Nguyen K.B., Cousens L.P., Doughty L.A., et al. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000, 1:70-76.
59. Meissner E.G., Wu D., Osinusi A., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014, 124:3352-3363.
60. Shin E.C., Seifert U., Kato T., et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 2006, 116:3006-3014.
61. Lau D.T., Negash A., Chen J., et al. Innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013, 144:402-413.
62. Dreux M., Garaigorta U., Boyd B., et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 2012, 12:558-570.
63. Takahashi K., Asabe S., Wieland S., et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci USA 2010, 107:7431-7436.
64. Giugliano S., Kriss M., Golden-Mason L., et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 2015, 148:392-402.e13.
65. Ahlenstiel G., Edlich B., Hogdal L.J., et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011, 141:1231-1239.
66. Stegmann K.A., Bjorkstrom N.K., Veber H., et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010, 138:1885-1897.
67. Oliviero B., Mele D., Degasperi E., et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol 2013, 59:38-44.
68. Chattergoon M.A., Latanich R., Quinn J., et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog 2014, 10:e1004082.
69. Negash A.A., Ramos H.J., Crochet N., et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013, 9:e1003330.
70. Serti E., Werner J.M., Chattergoon M., et al. Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology 2014, 147:209-220.
71. Chattergoon M.A., Levine J.S., Latanich R., et al. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis 2011, 204:1730-1740.
72. Jinushi M., Takehara T., Kanto T., et al. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003, 170:1249-1256.
73. Jinushi M., Takehara T., Tatsumi T., et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 2003, 171:5423-5429.
74. Jinushi M., Takehara T., Tatsumi T., et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004, 173:6072-6081.
75. Nattermann J., Nischalke H.D., Hofmeister V., et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005, 166:443-453.
76. Kramer B., Korner C., Kebschull M., et al. NKp46(High) expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis. Hepatology 2012, 56:1201-1213.
77. Larkin J., Bost A., Glass J.I., et al. Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. J Infect Dis 2006, 26:854-865.
78. Guidotti L.G., Chisari F.V. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996, 8:478-483.
79. + T cells in chronic hepatitis C virus infection. J Immunol 2002, 169:3447-3458.
80. Dunn C., Peppa D., Khanna P., et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009, 137:1289-1300.
81. Wieland S., Thimme R., Purcell R.H., et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004, 101:6669-6674.
82. Duan X.Z., Wang M., Li H.W., et al. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 2004, 24:637-646.
83. Zou Z., Xu D., Li B., et al. Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure. Hepatol Res 2009, 39:1198-1207.
84. Peppa D., Micco L., Javaid A., et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathogens 2010, 6:e1001227.
85. Tjwa E.T., van Oord G.W., Hegmans J.P., et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011, 54:209-218.
86. Heiberg I.L., Pallett L.J., Winther T.N., et al. Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clin Exp Immunol 2015, 179:466-476.
87. Das A., Ellis G., Pallant C., et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 2012, 189:3925-3935.
88. Ando K., Moriyama T., Guidotti L.G., et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993, 178:1541-1554.
89. Cavanaugh V.J., Guidotti L.G., Chisari F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997, 71:3236-3243.
90. Cheong J.Y., Cho S.W., Hwang I.L., et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol 2006, 21:1163-1169.
91. Miyazoe S., Hamasaki K., Nakata K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002, 97:2086-2092.
92. Dunn C., Brunetto M., Reynolds G., et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007, 204:667-680.
93. Peppa D., Gill U.S., Reynolds G., et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013, 210:99-114.
94. Waggoner S.N., Cornberg M., Selin L.K., et al. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012, 481:394-398.
95. Lang P.A., Lang K.S., Xu H.C., et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA 2012, 109:1210-1215.
96. Welsh R.M., Waggoner S.N. NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. Virology 2013, 435:37-45.
97. Rehermann B. Pathogenesis of chronic viral hepatitis. Differential roles of T cells and NK cells. Nat Med 2013, 19:859-868.
98. + T-cell function. Hepatology 2010, 52:1934-1947.
99. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010, 6:e1000947.
100. Nakamoto N., Cho H., Shaked A., et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313.
101. + T cells. J Virol 2009, 83:9122-9130.
102. Wherry E.J. T cell exhaustion. Nat Immunol 2011, 12:492-499.
103. Rehermann B., Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015, 61:712-721.
104. Rahman F., Heller T., Sobao Y., et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004, 40:87-97.
105. + T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005, 79:12979-12988.
106. Missale G., Pilli M., Zerbini A., et al. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 2012, 61:1076-1084.
107. Spaan M., van Oord G., Kreefft K., et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 2015, Published online. http://dx.doi.org/10.1093/infdis/jiv391.
108. + T cell function by interferon-free therapy. J Hepatol 2014, 61. 1219-1219.
109. Kwon H., Lok A.S. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011, 8:275-284.
110. Wursthorn K., Jung M., Riva A., et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010, 52:1611-1620.
111. Boni C., Laccabue D., Lampertico P., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012, 143:963-973.
112. Boni C., Penna A., Bertoletti A., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003, 39:595-605.
113. + T cell population in chronic hepatitis C virus infection. J Clin Invest 2004, 113:963-972.
114. Semmo N., Krashias G., Willberg C., et al. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J Viral Hepat 2007, 14:492-502.